|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: RAD18 |
Gene summary for RAD18 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | RAD18 | Gene ID | 56852 |
| Gene name | RAD18 E3 ubiquitin protein ligase | |
| Gene Alias | RNF73 | |
| Cytomap | 3p25.3 | |
| Gene Type | protein-coding | GO ID | GO:0006139 | UniProtAcc | Q9NS91 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 56852 | RAD18 | CCI_2 | Human | Cervix | CC | 9.84e-06 | 5.21e-01 | 0.5249 |
| 56852 | RAD18 | CCI_3 | Human | Cervix | CC | 1.22e-09 | 6.55e-01 | 0.516 |
| Page: 1 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Cervix |  | CC: Cervix cancer |
| HSIL_HPV: HPV-infected high-grade squamous intraepithelial lesions | ||
| N_HPV: HPV-infected normal cervix |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:00518656 | Cervix | CC | protein autoubiquitination | 17/2311 | 73/18723 | 6.71e-03 | 3.70e-02 | 17 |
| Page: 1 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| RAD18 | SNV | Missense_Mutation | c.211G>A | p.Asp71Asn | p.D71N | Q9NS91 | protein_coding | deleterious(0) | probably_damaging(0.978) | TCGA-AR-A0TS-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | doxorubicin | SD | |
| RAD18 | SNV | Missense_Mutation | c.653N>C | p.Lys218Thr | p.K218T | Q9NS91 | protein_coding | deleterious(0.01) | probably_damaging(0.948) | TCGA-D8-A1XK-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | doxorubicine+cyclophosphamide | SD | |
| RAD18 | SNV | Missense_Mutation | c.1393N>A | p.Leu465Ile | p.L465I | Q9NS91 | protein_coding | tolerated(0.22) | benign(0.058) | TCGA-D8-A27V-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Hormone Therapy | tamoxiphen | SD | |
| RAD18 | SNV | Missense_Mutation | c.269N>T | p.Asn90Ile | p.N90I | Q9NS91 | protein_coding | deleterious(0.01) | benign(0.071) | TCGA-E2-A14S-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Chemotherapy | cytoxan | SD | |
| RAD18 | insertion | Frame_Shift_Ins | rs766463274 | c.1111_1112insA | p.Thr371AsnfsTer9 | p.T371Nfs*9 | Q9NS91 | protein_coding | TCGA-AN-A0AK-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | ||
| RAD18 | SNV | Missense_Mutation | rs187913630 | c.338N>A | p.Val114Ile | p.V114I | protein_coding | unknown(0) | TCGA-EA-A410-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD | ||
| RAD18 | SNV | Missense_Mutation | novel | c.311N>A | p.Pro104His | p.P104H | Q9NS91 | protein_coding | deleterious(0) | possibly_damaging(0.847) | TCGA-UC-A7PF-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD |
| RAD18 | SNV | Missense_Mutation | rs769975828 | c.265N>T | p.Arg89Trp | p.R89W | Q9NS91 | protein_coding | deleterious(0) | probably_damaging(0.993) | TCGA-A6-2677-01 | Colorectum | colon adenocarcinoma | Female | >=65 | III/IV | Ancillary | leucovorin | SD |
| RAD18 | SNV | Missense_Mutation | novel | c.5A>T | p.Asp2Val | p.D2V | Q9NS91 | protein_coding | deleterious_low_confidence(0.01) | benign(0.273) | TCGA-AA-A010-01 | Colorectum | colon adenocarcinoma | Female | <65 | I/II | Chemotherapy | folinic | CR |
| RAD18 | SNV | Missense_Mutation | rs781347031 | c.679N>A | p.Glu227Lys | p.E227K | Q9NS91 | protein_coding | tolerated(0.05) | benign(0.08) | TCGA-AZ-4315-01 | Colorectum | colon adenocarcinoma | Male | <65 | I/II | Unknown | Unknown | SD |
| Page: 1 2 3 4 5 6 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |